Michael A. Schwarzschild - Publications

Affiliations: 
Neurology Massachusetts General Hospital and Harvard Medical School, Boston, MA, United States 

172 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2022 Page A, Yung N, Auinger P, Venuto C, Glidden A, Macklin E, Omberg L, Schwarzschild MA, Dorsey ER. A Smartphone Application as an Exploratory Endpoint in a Phase 3 Parkinson's Disease Clinical Trial: A Pilot Study. Digital Biomarkers. 6: 1-8. PMID 35224425 DOI: 10.1159/000521232  0.309
2022 Sanchez AV, Ison JM, Hemley H, Willis A, Siddiqi B, Macklin EA, Ulysse C, Reynolds M, Schwarzschild MA, Jackson JD. Designing the fostering inclusivity in research engagement for underrepresented populations in Parkinson's disease study. Contemporary Clinical Trials. 106713. PMID 35202842 DOI: 10.1016/j.cct.2022.106713  0.312
2022 Cai W, Srivastava P, Feng D, Lin Y, Vanderburg CR, Xu Y, Mclean P, Frosch MP, Fisher DE, Schwarzschild MA, Chen X. Melanocortin 1 receptor activation protects against alpha-synuclein pathologies in models of Parkinson's disease. Molecular Neurodegeneration. 17: 16. PMID 35197079 DOI: 10.1186/s13024-022-00520-4  0.673
2022 Zhang X, Molsberry SA, Yeh TS, Cassidy A, Schwarzschild MA, Ascherio A, Gao X. Intake of Flavonoids and Flavonoid-Rich Foods, and Mortality Risk Among Individuals With Parkinson Disease: A Prospective Cohort Study. Neurology. PMID 35082171 DOI: 10.1212/WNL.0000000000013275  0.335
2022 Macklin EA, Ascherio A, Schwarzschild MA. Effect of Urate-Elevating Inosine on Progression of Early Parkinson Disease-Reply. Jama. 327: 85-86. PMID 34982121 DOI: 10.1001/jama.2021.21011  0.305
2021 Lungu C, Cedarbaum JM, Dawson TM, Dorsey ER, Faraco C, Federoff HJ, Fiske B, Fox R, Goldfine AM, Kieburtz K, Macklin EA, Matthews H, Rafaloff G, Saunders-Pullman R, Schor NF, ... Schwarzschild MA, et al. Seeking progress in disease modification in Parkinson disease. Parkinsonism & Related Disorders. PMID 34561166 DOI: 10.1016/j.parkreldis.2021.09.006  0.356
2021 Schwarzschild MA, Ascherio A, Casaceli C, Curhan GC, Fitzgerald R, Kamp C, Lungu C, Macklin EA, Marek K, Mozaffarian D, Oakes D, Rudolph A, Shoulson I, Videnovic A, et al. Effect of Urate-Elevating Inosine on Early Parkinson Disease Progression: The SURE-PD3 Randomized Clinical Trial. Jama. 326: 926-939. PMID 34519802 DOI: 10.1001/jama.2021.10207  0.372
2021 Liu G, Peng J, Liao Z, Locascio JJ, Corvol JC, Zhu F, Dong X, Maple-Grødem J, Campbell MC, Elbaz A, Lesage S, Brice A, Mangone G, Growdon JH, Hung AY, ... Schwarzschild MA, et al. Genome-wide survival study identifies a novel synaptic locus and polygenic score for cognitive progression in Parkinson's disease. Nature Genetics. PMID 33958783 DOI: 10.1038/s41588-021-00847-6  0.556
2021 Zhang X, Molsberry SA, Pavlova M, Schwarzschild MA, Ascherio A, Gao X. Association of Sleepwalking and REM Sleep Behavior Disorder With Parkinson Disease in Men. Jama Network Open. 4: e215713. PMID 33847749 DOI: 10.1001/jamanetworkopen.2021.5713  0.305
2021 Tanner CM, Cummings SR, Schwarzschild MA, Brown EG, Dorsey ER, Espay AJ, Galifianakis NB, Goldman SM, Litvan I, Luthra N, McFarland NR, Mitchell KT, Standaert DG, Bauer DC, Greenspan SL, et al. The TOPAZ study: a home-based trial of zoledronic acid to prevent fractures in neurodegenerative parkinsonism. Npj Parkinson's Disease. 7: 16. PMID 33649343 DOI: 10.1038/s41531-021-00162-1  0.59
2020 Schneider RB, Omberg L, Macklin EA, Daeschler M, Bataille L, Anthwal S, Myers TL, Baloga E, Duquette S, Snyder P, Amodeo K, Tarolli CG, Adams JL, Callahan KF, Gottesman J, ... ... Schwarzschild MA, et al. Design of a virtual longitudinal observational study in Parkinson's disease (AT-HOME PD). Annals of Clinical and Translational Neurology. PMID 33350601 DOI: 10.1002/acn3.51236  0.316
2020 Chen JF, Schwarzschild MA. Do caffeine and more selective adenosine A receptor antagonists protect against dopaminergic neurodegeneration in Parkinson's disease? Parkinsonism & Related Disorders. 45-53. PMID 33349580 DOI: 10.1016/j.parkreldis.2020.10.024  0.39
2020 Simuni T, Fiske B, Merchant K, Coffey CS, Klingner E, Caspell-Garcia C, Lafontant DE, Matthews H, Wyse RK, Brundin P, Simon DK, Schwarzschild M, Weiner D, Adams J, Venuto C, et al. Efficacy of Nilotinib in Patients With Moderately Advanced Parkinson Disease: A Randomized Clinical Trial. Jama Neurology. PMID 33315105 DOI: 10.1001/jamaneurol.2020.4725  0.341
2020 Hung AY, Schwarzschild MA. Approaches to Disease Modification for Parkinson's Disease: Clinical Trials and Lessons Learned. Neurotherapeutics : the Journal of the American Society For Experimental Neurotherapeutics. PMID 33205384 DOI: 10.1007/s13311-020-00964-w  0.327
2020 Crotty GF, Maciuca R, Macklin EA, Wang J, Montalban M, Davis SS, Alkabsh JI, Bakshi R, Chen X, Ascherio A, Astarita G, Huntwork-Rodriguez S, Schwarzschild MA. Association of caffeine and related analytes with resistance to Parkinson's disease among mutation carriers: A metabolomic study. Neurology. PMID 32999056 DOI: 10.1212/WNL.0000000000010863  0.313
2020 Schootemeijer S, van der Kolk NM, Ellis T, Mirelman A, Nieuwboer A, Nieuwhof F, Schwarzschild MA, de Vries NM, Bloem BR. Barriers and Motivators to Engage in Exercise for Persons with Parkinson's Disease. Journal of Parkinson's Disease. PMID 32925106 DOI: 10.3233/Jpd-202247  0.365
2020 Molsberry S, Bjornevik K, Hughes KC, Healy B, Schwarzschild M, Ascherio A. Diet pattern and prodromal features of Parkinson's disease. Neurology. PMID 32817391 DOI: 10.1212/Wnl.0000000000010523  0.43
2020 Hasimoglu YG, Chen X, Bakshi R, Schwarzschild MA, Macklin EA. Does Serum Urate Change as Parkinson's Disease Progresses? Journal of Parkinson's Disease. 10: 1571-1576. PMID 32773396 DOI: 10.3233/Jpd-202064  0.445
2020 Ma C, Molsberry S, Li Y, Schwarzschild M, Ascherio A, Gao X. Dietary nicotine intake and risk of Parkinson disease: a prospective study. The American Journal of Clinical Nutrition. PMID 32725131 DOI: 10.1093/Ajcn/Nqaa186  0.437
2020 Crotty GF, Schwarzschild MA. Chasing Protection in Parkinson's Disease: Does Exercise Reduce Risk and Progression? Frontiers in Aging Neuroscience. 12: 186. PMID 32636740 DOI: 10.3389/Fnagi.2020.00186  0.446
2020 Huh YE, Ruby Chiang MS, Locascio JJ, Liao Z, Liu G, Choudhury K, Kuras YI, Tuncali I, Videnovic A, Hunt AL, Schwarzschild MA, Hung AY, Herrington TM, Hayes MT, Hyman BT, et al. β-Glucocerebrosidase Activity in -linked Parkinson's Disease: The Type of Mutation Matters. Neurology. PMID 32540937 DOI: 10.1212/Wnl.0000000000009989  0.621
2020 Palacios N, O'Reilly ÉJ, Schwarzschild MA, Ascherio A. Long-Term Use of Antibiotics and Risk of Parkinson's Disease in the Nurses' Health Study. Parkinson's Disease. 2020: 4038375. PMID 32399169 DOI: 10.1155/2020/4038375  0.38
2020 Bakshi R, Macklin EA, Hung AY, Hayes MT, Hyman BT, Wills AM, Gomperts SN, Growdon JH, Ascherio A, Scherzer CR, Schwarzschild MA. Associations of Lower Caffeine Intake and Plasma Urate Levels with Idiopathic Parkinson's Disease in the Harvard Biomarkers Study. Journal of Parkinson's Disease. 10: 505-510. PMID 32250320 DOI: 10.3233/Jpd-191882  0.67
2020 Molsberry S, Bjornevik K, Hughes KC, Zhang ZJ, Jeanfavre S, Clish C, Healy B, Schwarzschild M, Ascherio A. Plasma Metabolomic Markers of Insulin Resistance and Diabetes and Rate of Incident Parkinson's Disease. Journal of Parkinson's Disease. PMID 32250318 DOI: 10.3233/Jpd-191896  0.345
2020 Espay AJ, Kalia LV, Gan-Or Z, Williams-Gray CH, Bedard PL, Rowe SM, Morgante F, Fasano A, Stecher B, Kauffman MA, Farrer MJ, Coffey CS, Schwarzschild MA, Sherer T, Postuma RB, et al. Disease modification and biomarker development in Parkinson disease: Revision or reconstruction? Neurology. PMID 32102975 DOI: 10.1212/Wnl.0000000000009107  0.469
2020 Bjornevik K, Schwarzschild MA, Ascherio A. Big health data and Parkinson's disease epidemiology: Challenges and opportunities. Parkinsonism & Related Disorders. 71: 58-59. PMID 31948788 DOI: 10.1016/J.Parkreldis.2020.01.001  0.363
2019 Hughes KC, Gao X, Molsberry S, Valeri L, Schwarzschild MA, Ascherio A. Physical activity and prodromal features of Parkinson disease. Neurology. PMID 31719136 DOI: 10.1212/Wnl.0000000000008567  0.347
2019 Alcalay RN, Kehoe C, Shorr E, Battista R, Hall A, Simuni T, Marder K, Wills AM, Naito A, Beck JC, Schwarzschild MA, Nance M. Genetic testing for Parkinson disease: current practice, knowledge, and attitudes among US and Canadian movement disorders specialists. Genetics in Medicine : Official Journal of the American College of Medical Genetics. PMID 31680121 DOI: 10.1038/S41436-019-0684-X  0.377
2019 Schwarzschild MA, Macklin EA, Bakshi R, Battacharyya S, Logan R, Espay AJ, Hung AY, Bwala G, Goetz CG, Russell DS, Goudreau JL, Parashos SA, Saint-Hilaire MH, Rudolph A, Hare JM, et al. Sex differences by design and outcome in the Safety of Urate Elevation in PD (SURE-PD) trial. Neurology. PMID 31484712 DOI: 10.1212/Wnl.0000000000008194  0.437
2019 Bakshi R, Macklin EA, Logan R, Zorlu MM, Xia N, Crotty GF, Zhang E, Chen X, Ascherio A, Schwarzschild MA. Higher urate in LRRK2 mutation carriers resistant to Parkinson's disease. Annals of Neurology. PMID 30761591 DOI: 10.1002/Ana.25436  0.444
2019 Espay AJ, Vizcarra JA, Marsili L, Lang AE, Simon DK, Merola A, Josephs KA, Fasano A, Morgante F, Savica R, Greenamyre JT, Cambi F, Yamasaki TR, Tanner CM, Gan-Or Z, ... ... Schwarzschild MA, et al. Revisiting protein aggregation as pathogenic in sporadic Parkinson and Alzheimer diseases. Neurology. 92: 329-337. PMID 30745444 DOI: 10.1212/Wnl.0000000000006926  0.383
2019 Ascherio A, Schwarzschild MA. Lifestyle and Parkinson's disease progression. Movement Disorders : Official Journal of the Movement Disorder Society. 34: 7-8. PMID 30653733 DOI: 10.1002/Mds.27566  0.423
2018 Chen X, Umeh CC, Tainsh RE, Feng DD, Maguire M, Zuo F, Rahimian M, Logan R, Wang X, Ascherio A, Macklin EA, Buys ES, Schwarzschild MA. Dissociation between urate and blood pressure in mice and in people with early Parkinson's disease. Ebiomedicine. PMID 30415890 DOI: 10.1016/J.Ebiom.2018.10.039  0.43
2018 Palacios N, Hughes KC, Cereda E, Schwarzschild MA, Ascherio A. Appendectomy and risk of Parkinson's disease in two large prospective cohorts of men and women. Movement Disorders : Official Journal of the Movement Disorder Society. PMID 30218460 DOI: 10.1002/Mds.109  0.428
2018 Iwaki H, Hughes KC, Gao X, Schwarzschild MA, Ascherio A. The association between restless legs syndrome and premotor symptoms of Parkinson's disease. Journal of the Neurological Sciences. 394: 41-44. PMID 30212740 DOI: 10.1016/J.Jns.2018.08.028  0.421
2018 Hughes KC, Gao X, Baker JM, Stephen C, Kim IY, Valeri L, Schwarzschild MA, Ascherio A. Non-motor features of Parkinson's disease in a nested case-control study of US men. Journal of Neurology, Neurosurgery, and Psychiatry. PMID 30076266 DOI: 10.1136/Jnnp-2018-318275  0.422
2018 Hughes KC, Gao X, O'Reilly EJ, Kim IY, Wang M, Weisskopf MG, Schwarzschild MA, Ascherio A. Genetic variants related to urate and risk of Parkinson's disease. Parkinsonism & Related Disorders. PMID 29789205 DOI: 10.1016/J.Parkreldis.2018.04.031  0.482
2018 Kim IY, O'Reilly ÉJ, Hughes KC, Gao X, Schwarzschild MA, Hannan MT, Betensky RA, Ascherio A. Integration of risk factors for Parkinson disease in 2 large longitudinal cohorts. Neurology. PMID 29643081 DOI: 10.1212/Wnl.0000000000005473  0.468
2018 Cai W, Feng D, Schwarzschild MA, McLean PJ, Chen X. Bimolecular Fluorescence Complementation of Alpha-synuclein Demonstrates its Oligomerization with Dopaminergic Phenotype in Mice. Ebiomedicine. PMID 29433982 DOI: 10.1016/J.Ebiom.2018.01.035  0.681
2018 Kim IY, O'Reilly ÉJ, Hughes KC, Gao X, Schwarzschild MA, McCullough ML, Hannan MT, Betensky RA, Ascherio A. Interaction between caffeine and polymorphisms of glutamate ionotropic receptor NMDA type subunit 2A (GRIN2A) and cytochrome P450 1A2 (CYP1A2) on Parkinson's disease risk. Movement Disorders : Official Journal of the Movement Disorder Society. PMID 29318639 DOI: 10.1002/Mds.27279  0.385
2017 Kim IY, O'Reilly ÉJ, Hughes KC, Gao X, Schwarzschild MA, Ascherio A. Differences in Parkinson's Disease Risk with Caffeine Intake and Postmenopausal Hormone Use. Journal of Parkinson's Disease. PMID 28984617 DOI: 10.3233/Jpd-171175  0.451
2017 Ascherio A, Schwarzschild MA. Dietary antioxidants and Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 32: 1501-1503. PMID 28976040 DOI: 10.1002/Mds.27194  0.409
2017 Crotty GF, Ascherio A, Schwarzschild MA. Targeting urate to reduce oxidative stress in Parkinson disease. Experimental Neurology. 298: 210-224. PMID 28622913 DOI: 10.1016/J.Expneurol.2017.06.017  0.455
2017 Hughes KC, Gao X, Kim IY, Wang M, Weisskopf MG, Schwarzschild MA, Ascherio A. Intake of dairy foods and risk of Parkinson disease. Neurology. PMID 28596209 DOI: 10.1212/Wnl.0000000000004057  0.439
2017 Chen X, Feng D, Schwarzschild MA, Gao X. Red hair, MC1R variants, and risk for Parkinson's disease - a meta-analysis. Annals of Clinical and Translational Neurology. 4: 212-216. PMID 28275654 DOI: 10.1002/Acn3.381  0.422
2017 Espay AJ, Schwarzschild MA, Tanner CM, Fernandez HH, Simon DK, Leverenz JB, Merola A, Chen-Plotkin A, Brundin P, Kauffman MA, Erro R, Kieburtz K, Woo D, Macklin EA, Standaert DG, et al. Biomarker-driven phenotyping in Parkinson's disease: A translational missing link in disease-modifying clinical trials. Movement Disorders : Official Journal of the Movement Disorder Society. PMID 28233927 DOI: 10.1002/Mds.26913  0.469
2016 Chen X, Chen H, Cai W, Maguire M, Ya B, Zuo F, Logan R, Li H, Robinson K, Vanderburg CR, Yu Y, Wang Y, Fisher DE, Schwarzschild MA. The melanoma-linked "redhead" MC1R influences dopaminergic neuron survival. Annals of Neurology. PMID 28019657 DOI: 10.1002/Ana.24852  0.419
2016 Paganoni S, Schwarzschild MA. Urate as a Marker of Risk and Progression of Neurodegenerative Disease. Neurotherapeutics : the Journal of the American Society For Experimental Neurotherapeutics. PMID 27995438 DOI: 10.1007/S13311-016-0497-4  0.489
2016 Hughes KC, Gao X, Kim IY, Rimm EB, Wang M, Weisskopf MG, Schwarzschild MA, Ascherio A. Intake of antioxidant vitamins and risk of parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. PMID 27787934 DOI: 10.1002/Mds.26819  0.405
2016 Ascherio A, Schwarzschild MA. The epidemiology of Parkinson's disease: risk factors and prevention. The Lancet. Neurology. 15: 1257-1272. PMID 27751556 DOI: 10.1016/S1474-4422(16)30230-7  0.425
2016 Xu K, Luca DG, Orrú M, Xu Y, Chen JF, Schwarzschild MA. Neuroprotection by caffeine in the MPTP model of Parkinson's disease and its dependence on adenosine A2A receptors. Neuroscience. PMID 26905951 DOI: 10.1016/J.Neuroscience.2016.02.035  0.444
2016 Bhattacharyya S, Bakshi R, Logan R, Ascherio A, Macklin EA, Schwarzschild MA. Oral Inosine Persistently Elevates Plasma antioxidant capacity in Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. PMID 26805433 DOI: 10.1002/Mds.26483  0.415
2016 Gao X, O'Reilly ÉJ, Schwarzschild MA, Ascherio A. Prospective study of plasma urate and risk of Parkinson disease in men and women. Neurology. PMID 26764029 DOI: 10.1212/Wnl.0000000000002351  0.461
2016 Schwarzschild M, Fitzgerald K, Bakshi R, Macklin E, Scherzer C, Ascherio A. Association of α-synuclein gene expression with Parkinson’s disease is attenuated with higher serum urate in the PPMI cohort Parkinsonism & Related Disorders. 22: e115. DOI: 10.1016/J.Parkreldis.2015.10.265  0.317
2015 Bakshi R, Zhang H, Logan R, Joshi I, Xu Y, Chen X, Schwarzschild MA. Neuroprotective effects of urate are mediated by augmenting astrocytic glutathione synthesis and release. Neurobiology of Disease. PMID 26341543 DOI: 10.1016/J.Nbd.2015.08.022  0.389
2015 Locascio JJ, Eberly S, Liao Z, Liu G, Hoesing AN, Duong K, Trisini-Lipsanopoulos A, Dhima K, Hung AY, Flaherty AW, Schwarzschild MA, Hayes MT, Wills AM, Shivraj Sohur U, Mejia NI, et al. Association between α-synuclein blood transcripts and early, neuroimaging-supported Parkinson's disease. Brain : a Journal of Neurology. 138: 2659-71. PMID 26220939 DOI: 10.1093/Brain/Awv202  0.65
2015 Chen X, Wales P, Quinti L, Zuo F, Moniot S, Herisson F, Rauf NA, Wang H, Silverman RB, Ayata C, Maxwell MM, Steegborn C, Schwarzschild MA, Outeiro TF, Kazantsev AG. The sirtuin-2 inhibitor AK7 is neuroprotective in models of Parkinson's disease but not amyotrophic lateral sclerosis and cerebral ischemia. Plos One. 10: e0116919. PMID 25608039 DOI: 10.1371/Journal.Pone.0116919  0.416
2015 Locascio JJ, Eberly S, Liao Z, Liu G, Hoesing AN, Duong K, Trisini-Lipsanopoulos A, Dhima K, Hung AY, Flaherty AW, Schwarzschild MA, Hayes MT, Wills AM, Shivraj Sohur U, Mejia NI, et al. Association between α-synuclein blood transcripts and early, neuroimaging-supported Parkinson's disease Brain. 138: 2659-2671. DOI: 10.1093/brain/awv202  0.591
2014 Palacios N, Fitzgerald KC, Hart JE, Weisskopf MG, Schwarzschild MA, Ascherio A, Laden F. Particulate matter and risk of Parkinson disease in a large prospective study of women. Environmental Health : a Global Access Science Source. 13: 80. PMID 25294559 DOI: 10.1186/1476-069X-13-80  0.387
2014 Simon KC, Eberly S, Gao X, Oakes D, Tanner CM, Shoulson I, Fahn S, Schwarzschild MA, Ascherio A. Mendelian randomization of serum urate and parkinson disease progression. Annals of Neurology. 76: 862-8. PMID 25257975 DOI: 10.1002/Ana.24281  0.452
2014 Palacios N, Fitzgerald K, Roberts AL, Hart JE, Weisskopf MG, Schwarzschild MA, Ascherio A, Laden F. A prospective analysis of airborne metal exposures and risk of Parkinson disease in the nurses' health study cohort. Environmental Health Perspectives. 122: 933-8. PMID 24905870 DOI: 10.1289/Ehp.1307218  0.403
2014 Cipriani S, Bakshi R, Schwarzschild MA. Protection by inosine in a cellular model of Parkinson's disease. Neuroscience. 274: 242-9. PMID 24880154 DOI: 10.1016/J.Neuroscience.2014.05.038  0.387
2014 Kachroo A, Schwarzschild MA. Allopurinol reduces levels of urate and dopamine but not dopaminergic neurons in a dual pesticide model of Parkinson's disease. Brain Research. 1563: 103-9. PMID 24680743 DOI: 10.1016/J.Brainres.2014.03.031  0.418
2014 Wong JC, Li Y, Schwarzschild MA, Ascherio A, Gao X. Restless legs syndrome: an early clinical feature of Parkinson disease in men. Sleep. 37: 369-72. PMID 24497665 DOI: 10.5665/Sleep.3416  0.416
2014 McFarland NR, Dimant H, Kibuuka L, Ebrahimi-Fakhari D, Desjardins CA, Danzer KM, Danzer M, Fan Z, Schwarzschild MA, Hirst W, McLean PJ. Chronic treatment with novel small molecule Hsp90 inhibitors rescues striatal dopamine levels but not α-synuclein-induced neuronal cell loss. Plos One. 9: e86048. PMID 24465863 DOI: 10.1371/Journal.Pone.0086048  0.722
2014 Schwarzschild MA, Ascherio A, Beal MF, Cudkowicz ME, Curhan GC, Hare JM, Hooper DC, Kieburtz KD, Macklin EA, Oakes D, Rudolph A, Shoulson I, Tennis MK, Espay AJ, et al. Inosine to increase serum and cerebrospinal fluid urate in Parkinson disease: a randomized clinical trial. Jama Neurology. 71: 141-50. PMID 24366103 DOI: 10.1001/Jamaneurol.2013.5528  0.42
2014 Hung AY, Schwarzschild MA. Treatment of Parkinson's disease: what's in the non-dopaminergic pipeline? Neurotherapeutics : the Journal of the American Society For Experimental Neurotherapeutics. 11: 34-46. PMID 24310604 DOI: 10.1007/S13311-013-0239-9  0.431
2013 Ding H, Dhima K, Lockhart KC, Locascio JJ, Hoesing AN, Duong K, Trisini-Lipsanopoulos A, Hayes MT, Sohur US, Wills AM, Mollenhauer B, Flaherty AW, Hung AY, Mejia N, Khurana V, ... ... Schwarzschild MA, et al. Unrecognized vitamin D3 deficiency is common in Parkinson disease: Harvard Biomarker Study. Neurology. 81: 1531-7. PMID 24068787 DOI: 10.1212/Wnl.0B013E3182A95818  0.629
2013 Brundin P, Barker RA, Conn PJ, Dawson TM, Kieburtz K, Lees AJ, Schwarzschild MA, Tanner CM, Isaacs T, Duffen J, Matthews H, Wyse RK. Linked clinical trials--the development of new clinical learning studies in Parkinson's disease using screening of multiple prospective new treatments. Journal of Parkinson's Disease. 3: 231-9. PMID 24018336 DOI: 10.3233/Jpd-139000  0.423
2013 McFarland NR, Burdett T, Desjardins CA, Frosch MP, Schwarzschild MA. Postmortem brain levels of urate and precursors in Parkinson's disease and related disorders. Neuro-Degenerative Diseases. 12: 189-98. PMID 23467193 DOI: 10.1159/000346370  0.685
2013 Wills AM, Eberly S, Tennis M, Lang AE, Messing S, Togasaki D, Tanner CM, Kamp C, Chen JF, Oakes D, McDermott MP, Schwarzschild MA. Caffeine consumption and risk of dyskinesia in CALM-PD. Movement Disorders : Official Journal of the Movement Disorder Society. 28: 380-3. PMID 23339054 DOI: 10.1002/Mds.25319  0.441
2013 Chen X, Burdett TC, Desjardins CA, Logan R, Cipriani S, Xu Y, Schwarzschild MA. Disrupted and transgenic urate oxidase alter urate and dopaminergic neurodegeneration. Proceedings of the National Academy of Sciences of the United States of America. 110: 300-5. PMID 23248282 DOI: 10.1073/Pnas.1217296110  0.456
2013 Burdett TC, Desjardins CA, Logan R, McFarland NR, Chen X, Schwarzschild MA. Efficient determination of purine metabolites in brain tissue and serum by high-performance liquid chromatography with electrochemical and UV detection. Biomedical Chromatography : Bmc. 27: 122-9. PMID 22674671 DOI: 10.1002/Bmc.2760  0.582
2013 McFarland NR, Burdett T, Desjardins CA, Frosch MP, Schwarzschild MA, Nocker M, Scherfler C, Kiechl S, Willeit J, Schmidauer C, Gasperi A, Rungger G, Poewe W, Mahlknecht P, Seppi K, et al. Contents Vol. 12, 2013 Neurodegenerative Diseases. 12. DOI: 10.1159/000355887  0.553
2012 Palacios N, Gao X, Schwarzschild M, Ascherio A. Declining quality of life in Parkinson disease before and after diagnosis. Journal of Parkinson's Disease. 2: 153-60. PMID 23939439 DOI: 10.3233/Jpd-2012-12083  0.376
2012 Gao X, Simon KC, Schwarzschild MA, Ascherio A. Age, statin use, and the risk for incident Parkinson disease-reply. Archives of Neurology. 69: 1381. PMID 23754004 DOI: 10.1001/Archneurol.2012.2032  0.369
2012 Ravina B, Marek K, Eberly S, Oakes D, Kurlan R, Ascherio A, Beal F, Beck J, Flagg E, Galpern WR, Harman J, Lang AE, Schwarzschild M, Tanner C, Shoulson I. Dopamine transporter imaging is associated with long-term outcomes in Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 27: 1392-7. PMID 22976926 DOI: 10.1002/Mds.25157  0.388
2012 Palacios N, Gao X, McCullough ML, Schwarzschild MA, Shah R, Gapstur S, Ascherio A. Caffeine and risk of Parkinson's disease in a large cohort of men and women. Movement Disorders : Official Journal of the Movement Disorder Society. 27: 1276-82. PMID 22927157 DOI: 10.1002/Mds.25076  0.412
2012 Schwarzschild MA. Caffeine in Parkinson disease: better for cruise control than snooze patrol? Neurology. 79: 616-8. PMID 22855870 DOI: 10.1212/Wnl.0B013E318263580E  0.392
2012 Palacios N, Gao X, O'Reilly E, Schwarzschild M, McCullough ML, Mayo T, Gapstur SM, Ascherio AA. Alcohol and risk of Parkinson's disease in a large, prospective cohort of men and women. Movement Disorders : Official Journal of the Movement Disorder Society. 27: 980-7. PMID 22714720 DOI: 10.1002/Mds.25050  0.337
2012 Cipriani S, Desjardins CA, Burdett TC, Xu Y, Xu K, Schwarzschild MA. Protection of dopaminergic cells by urate requires its accumulation in astrocytes. Journal of Neurochemistry. 123: 172-81. PMID 22671773 DOI: 10.1111/J.1471-4159.2012.07820.X  0.338
2012 Cipriani S, Desjardins CA, Burdett TC, Xu Y, Xu K, Schwarzschild MA. Urate and its transgenic depletion modulate neuronal vulnerability in a cellular model of Parkinson's disease. Plos One. 7: e37331. PMID 22606360 DOI: 10.1371/Journal.Pone.0037331  0.334
2012 Chen X, Wu G, Schwarzschild MA. Urate in Parkinson's disease: more than a biomarker? Current Neurology and Neuroscience Reports. 12: 367-75. PMID 22580741 DOI: 10.1007/S11910-012-0282-7  0.492
2012 Gao X, Cassidy A, Schwarzschild MA, Rimm EB, Ascherio A. Habitual intake of dietary flavonoids and risk of Parkinson disease. Neurology. 78: 1138-45. PMID 22491871 DOI: 10.1212/Wnl.0B013E31824F7Fc4  0.409
2012 Gao X, Simon KC, Schwarzschild MA, Ascherio A. Prospective study of statin use and risk of Parkinson disease. Archives of Neurology. 69: 380-4. PMID 22410446 DOI: 10.1001/Archneurol.2011.1060  0.438
2012 Kachroo A, Schwarzschild MA. Adenosine A2A receptor gene disruption protects in an α-synuclein model of Parkinson's disease. Annals of Neurology. 71: 278-82. PMID 22367999 DOI: 10.1002/Ana.22630  0.446
2012 Palacios N, Gao X, Schwarzschild M, Ascherio A. Declining Quality of Life in Parkinson Disease Patients before and after Diagnosis (P06.064) Neurology. 78: P06.064-P06.064. DOI: 10.1212/Wnl.78.1_Meetingabstracts.P06.064  0.313
2012 Palacios N, Roberts A, Weisskopf M, Schwarzschild M, Laden F, Ascherio A. E-002: Exposure to Airborne Metals and risk of Parkinson Disease in a Prospective Study of US Women Epidemiology. 23: 1. DOI: 10.1097/01.Ede.0000416602.63176.B5  0.327
2012 Chen X, Burdett T, Desjardins C, Xu Y, Schwarzschild MA. 3.245 Effects Of Urate Oxidase Transgene Or Knockout In A Mouse Model Of Parkinson'S Disease Parkinsonism & Related Disorders. 18. DOI: 10.1016/S1353-8020(11)70917-8  0.407
2012 Gao X, Simon K, Schwarzschild M, Ascherio A. 1.120 A PROSPECTIVE STUDY OF STATIN USE AND RISK OF PARKINSON DISEASE Parkinsonism & Related Disorders. 18: S40. DOI: 10.1016/S1353-8020(11)70234-6  0.401
2011 Ding H, Sarokhan AK, Roderick SS, Bakshi R, Maher NE, Ashourian P, Kan CG, Chang S, Santarlasci A, Swords KE, Ravina BM, Hayes MT, Sohur US, Wills AM, Flaherty AW, ... ... Schwarzschild MA, et al. Association of SNCA with Parkinson: replication in the Harvard NeuroDiscovery Center Biomarker Study. Movement Disorders : Official Journal of the Movement Disorder Society. 26: 2283-6. PMID 21953863 DOI: 10.1002/Mds.23934  0.645
2011 Huang X, Auinger P, Eberly S, Oakes D, Schwarzschild M, Ascherio A, Mailman R, Chen H. Serum cholesterol and the progression of parkinson's disease: Results from DATATOP Plos One. 6. PMID 21853051 DOI: 10.1371/Journal.Pone.0022854  0.448
2011 Palacios N, Gao X, McCullough ML, Jacobs EJ, Patel AV, Mayo T, Schwarzschild MA, Ascherio A. Obesity, diabetes, and risk of Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 26: 2253-9. PMID 21739472 DOI: 10.1002/Mds.23855  0.371
2011 Gao X, Chen H, Schwarzschild MA, Ascherio A. A prospective study of bowel movement frequency and risk of Parkinson's disease. American Journal of Epidemiology. 174: 546-51. PMID 21719744 DOI: 10.1093/Aje/Kwr119  0.336
2011 Schwarzschild MA, Marek K, Eberly S, Oakes D, Shoulson I, Jennings D, Seibyl J, Ascherio A. Serum urate and probability of dopaminergic deficit in early "Parkinson's disease". Movement Disorders : Official Journal of the Movement Disorder Society. 26: 1864-8. PMID 21538532 DOI: 10.1002/Mds.23741  0.397
2011 Gao X, Chen H, Schwarzschild MA, Ascherio A. Use of ibuprofen and risk of Parkinson disease. Neurology. 76: 863-9. PMID 21368281 DOI: 10.1212/Wnl.0B013E31820F2D79  0.449
2011 Barkhoudarian MT, Schwarzschild MA. Preclinical jockeying on the translational track of adenosine A2A receptors. Experimental Neurology. 228: 160-4. PMID 21211537 DOI: 10.1016/J.Expneurol.2010.12.022  0.391
2011 Xiao D, Cassin JJ, Healy B, Burdett TC, Chen JF, Fredholm BB, Schwarzschild MA. Deletion of adenosine A₁ or A(â‚‚A) receptors reduces L-3,4-dihydroxyphenylalanine-induced dyskinesia in a model of Parkinson's disease. Brain Research. 1367: 310-8. PMID 20828543 DOI: 10.1016/J.Brainres.2010.08.099  0.411
2010 Cipriani S, Chen X, Schwarzschild MA. Urate: a novel biomarker of Parkinson's disease risk, diagnosis and prognosis. Biomarkers in Medicine. 4: 701-12. PMID 20945982 DOI: 10.2217/Bmm.10.94  0.476
2010 Black YD, Xiao D, Pellegrino D, Kachroo A, Brownell AL, Schwarzschild MA. Protective effect of metabotropic glutamate mGluR5 receptor elimination in a 6-hydroxydopamine model of Parkinson's disease. Neuroscience Letters. 486: 161-5. PMID 20854878 DOI: 10.1016/J.Neulet.2010.09.043  0.428
2010 Gardener H, Gao X, Chen H, Schwarzschild MA, Spiegelman D, Ascherio A. Prenatal and early life factors and risk of Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 25: 1560-7. PMID 20740569 DOI: 10.1002/Mds.23339  0.421
2010 Gao X, Schwarzschild MA, O'Reilly EJ, Wang H, Ascherio A. Restless legs syndrome and Parkinson's disease in men. Movement Disorders : Official Journal of the Movement Disorder Society. 25: 2654-7. PMID 20737545 DOI: 10.1002/Mds.23256  0.442
2010 Morelli M, Carta AR, Kachroo A, Schwarzschild MA. Pathophysiological roles for purines: adenosine, caffeine and urate. Progress in Brain Research. 183: 183-208. PMID 20696321 DOI: 10.1016/S0079-6123(10)83010-9  0.473
2010 O'Reilly EJ, Gao X, Weisskopf MG, Chen H, Schwarzschild MA, Spiegelman D, Ascherio A. Plasma urate and Parkinson's disease in women. American Journal of Epidemiology. 172: 666-70. PMID 20682521 DOI: 10.1093/Aje/Kwq195  0.34
2010 Simon KC, Gao X, Chen H, Schwarzschild MA, Ascherio A. Calcium channel blocker use and risk of Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 25: 1818-22. PMID 20669249 DOI: 10.1002/Mds.23191  0.451
2010 Palacios N, Weisskopf M, Simon K, Gao X, Schwarzschild M, Ascherio A. Polymorphisms of caffeine metabolism and estrogen receptor genes and risk of Parkinson's disease in men and women. Parkinsonism & Related Disorders. 16: 370-5. PMID 20304699 DOI: 10.1016/J.Parkreldis.2010.02.012  0.403
2010 Kachroo A, Irizarry MC, Schwarzschild MA. Caffeine protects against combined paraquat and maneb-induced dopaminergic neuron degeneration. Experimental Neurology. 223: 657-61. PMID 20188092 DOI: 10.1016/J.Expneurol.2010.02.007  0.445
2010 Schwarzschild MA. Rasagiline in Parkinson's disease. The New England Journal of Medicine. 362: 658; author reply 65. PMID 20187261  0.314
2010 Xu K, Xu YH, Chen JF, Schwarzschild MA. Neuroprotection by caffeine: time course and role of its metabolites in the MPTP model of Parkinson's disease. Neuroscience. 167: 475-81. PMID 20167258 DOI: 10.1016/J.Neuroscience.2010.02.020  0.411
2009 Gao X, Simon KC, Han J, Schwarzschild MA, Ascherio A. Family history of melanoma and Parkinson disease risk. Neurology. 73: 1286-91. PMID 19841380 DOI: 10.1212/Wnl.0B013E3181Bd13A1  0.447
2009 Ascherio A, LeWitt PA, Xu K, Eberly S, Watts A, Matson WR, Marras C, Kieburtz K, Rudolph A, Bogdanov MB, Schwid SR, Tennis M, Tanner CM, Beal MF, Lang AE, ... ... Schwarzschild MA, et al. Urate as a predictor of the rate of clinical decline in Parkinson disease. Archives of Neurology. 66: 1460-8. PMID 19822770 DOI: 10.1001/Archneurol.2009.247  0.408
2009 Carta AR, Kachroo A, Schintu N, Xu K, Schwarzschild MA, Wardas J, Morelli M. Inactivation of neuronal forebrain A receptors protects dopaminergic neurons in a mouse model of Parkinson's disease. Journal of Neurochemistry. 111: 1478-89. PMID 19817968 DOI: 10.1111/J.1471-4159.2009.06425.X  0.447
2009 McFarland NR, Fan Z, Xu K, Schwarzschild MA, Feany MB, Hyman BT, McLean PJ. Alpha-synuclein S129 phosphorylation mutants do not alter nigrostriatal toxicity in a rat model of Parkinson disease. Journal of Neuropathology and Experimental Neurology. 68: 515-24. PMID 19525899 DOI: 10.1097/Nen.0B013E3181A24B53  0.741
2009 Simon KC, Chen H, Gao X, Schwarzschild MA, Ascherio A. Reproductive factors, exogenous estrogen use, and risk of Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 24: 1359-65. PMID 19424986 DOI: 10.1002/Mds.22619  0.441
2009 Gao X, Simon KC, Han J, Schwarzschild MA, Ascherio A. Genetic determinants of hair color and Parkinson's disease risk. Annals of Neurology. 65: 76-82. PMID 19194882 DOI: 10.1002/Ana.21535  0.462
2009 Bronstein J, Carvey P, Chen H, Cory-Slechta D, DiMonte D, Duda J, English P, Goldman S, Grate S, Hansen J, Hoppin J, Jewell S, Kamel F, Koroshetz W, Langston JW, ... ... Schwarzschild M, et al. Meeting report: consensus statement-Parkinson's disease and the environment: collaborative on health and the environment and Parkinson's Action Network (CHE PAN) conference 26-28 June 2007. Environmental Health Perspectives. 117: 117-21. PMID 19165397 DOI: 10.1289/Ehp.11702  0.46
2009 O'Reilly EJ, Chen H, Gardener H, Gao X, Schwarzschild MA, Ascherio A. Smoking and Parkinson's disease: using parental smoking as a proxy to explore causality. American Journal of Epidemiology. 169: 678-82. PMID 19131566 DOI: 10.1093/Aje/Kwn388  0.349
2009 Petzer JP, Castagnoli N, Schwarzschild MA, Chen JF, Van der Schyf CJ. Dual-target-directed drugs that block monoamine oxidase B and adenosine A(2A) receptors for Parkinson's disease. Neurotherapeutics : the Journal of the American Society For Experimental Neurotherapeutics. 6: 141-51. PMID 19110205 DOI: 10.1016/J.Nurt.2008.10.035  0.42
2008 Schwarzschild MA, Schwid SR, Marek K, Watts A, Lang AE, Oakes D, Shoulson I, Ascherio A, Hyson C, Gorbold E, Rudolph A, Kieburtz K, Fahn S, Gauger L, et al. Serum urate as a predictor of clinical and radiographic progression in Parkinson disease. Archives of Neurology. 65: 716-23. PMID 18413464 DOI: 10.1001/Archneur.2008.65.6.Nct70003  0.437
2008 Gao X, Chen H, Choi HK, Curhan G, Schwarzschild MA, Ascherio A. Diet, urate, and Parkinson's disease risk in men. American Journal of Epidemiology. 167: 831-8. PMID 18326873 DOI: 10.1093/Aje/Kwm385  0.453
2008 Gao X, Chen H, Schwarzschild MA, Logroscino G, Ascherio A. Perceived imbalance and risk of Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 23: 613-6. PMID 18181208 DOI: 10.1002/Mds.21919  0.47
2008 Wang H, Chen H, Gao X, McGrath M, Deer D, De Vivo I, Schwarzschild MA, Ascherio A. Telomere length and risk of Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 23: 302-5. PMID 18044760 DOI: 10.1002/Mds.21867  0.458
2008 Thacker EL, Chen H, Patel AV, McCullough ML, Calle EE, Thun MJ, Schwarzschild MA, Ascherio A. Recreational physical activity and risk of Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 23: 69-74. PMID 17960818 DOI: 10.1002/Mds.21772  0.419
2008 Chen H, O'Reilly EJ, Schwarzschild MA, Ascherio A. Peripheral inflammatory biomarkers and risk of Parkinson's disease. American Journal of Epidemiology. 167: 90-5. PMID 17890755 DOI: 10.1093/Aje/Kwm260  0.357
2008 McFarland NR, Schwarzschild MA. Is Mortality Increased with Essential Tremor Nejm Journal Watch. 2008. DOI: 10.1056/Jn200803110000003  0.575
2007 Schwarzschild MA. Adenosine A2A antagonists as neurotherapeutics: crossing the bridge. Progress in Neurobiology. 83: 261-2. PMID 17997007 DOI: 10.1016/J.Pneurobio.2007.10.002  0.342
2007 Gao X, Chen H, Fung TT, Logroscino G, Schwarzschild MA, Hu FB, Ascherio A. Prospective study of dietary pattern and risk of Parkinson disease. The American Journal of Clinical Nutrition. 86: 1486-94. PMID 17991663 DOI: 10.1093/Ajcn/86.5.1486  0.416
2007 Gao X, Chen H, Schwarzschild MA, Glasser DB, Logroscino G, Rimm EB, Ascherio A. Erectile function and risk of Parkinson's disease. American Journal of Epidemiology. 166: 1446-50. PMID 17875583 DOI: 10.1093/Aje/Kwm246  0.379
2007 Morelli M, Di Paolo T, Wardas J, Calon F, Xiao D, Schwarzschild MA. Role of adenosine A2A receptors in parkinsonian motor impairment and l-DOPA-induced motor complications. Progress in Neurobiology. 83: 293-309. PMID 17826884 DOI: 10.1016/J.Pneurobio.2007.07.001  0.418
2007 Simon KC, Chen H, Schwarzschild M, Ascherio A. Hypertension, hypercholesterolemia, diabetes, and risk of Parkinson disease. Neurology. 69: 1688-95. PMID 17761552 DOI: 10.1212/01.Wnl.0000271883.45010.8A  0.431
2007 Hung AY, Schwarzschild MA. Clinical trials for neuroprotection in Parkinson's disease: overcoming angst and futility? Current Opinion in Neurology. 20: 477-83. PMID 17620885 DOI: 10.1097/Wco.0B013E32826388D6  0.383
2007 Weisskopf MG, O'Reilly E, Chen H, Schwarzschild MA, Ascherio A. Plasma urate and risk of Parkinson's disease. American Journal of Epidemiology. 166: 561-7. PMID 17584757 DOI: 10.1093/Aje/Kwm127  0.453
2007 Thacker EL, O'Reilly EJ, Weisskopf MG, Chen H, Schwarzschild MA, McCullough ML, Calle EE, Thun MJ, Ascherio A. Temporal relationship between cigarette smoking and risk of Parkinson disease. Neurology. 68: 764-8. PMID 17339584 DOI: 10.1212/01.Wnl.0000256374.50227.4B  0.33
2007 Chen H, O'Reilly E, McCullough ML, Rodriguez C, Schwarzschild MA, Calle EE, Thun MJ, Ascherio A. Consumption of dairy products and risk of Parkinson's disease. American Journal of Epidemiology. 165: 998-1006. PMID 17272289 DOI: 10.1093/Aje/Kwk089  0.321
2007 Scherzer CR, Eklund AC, Morse LJ, Liao Z, Locascio JJ, Fefer D, Schwarzschild MA, Schlossmacher MG, Hauser MA, Vance JM, Sudarsky LR, Standaert DG, Growdon JH, Jensen RV, Gullans SR. Molecular markers of early Parkinson's disease based on gene expression in blood. Proceedings of the National Academy of Sciences of the United States of America. 104: 955-60. PMID 17215369 DOI: 10.1073/Pnas.0610204104  0.621
2006 Xiao D, Bastia E, Xu YH, Benn CL, Cha JH, Peterson TS, Chen JF, Schwarzschild MA. Forebrain adenosine A2A receptors contribute to L-3,4-dihydroxyphenylalanine-induced dyskinesia in hemiparkinsonian mice. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 26: 13548-55. PMID 17192438 DOI: 10.1523/Jneurosci.3554-06.2006  0.408
2006 Schwarzschild MA, Agnati L, Fuxe K, Chen JF, Morelli M. Targeting adenosine A2A receptors in Parkinson's disease. Trends in Neurosciences. 29: 647-54. PMID 17030429 DOI: 10.1016/J.Tins.2006.09.004  0.466
2006 Schapira AH, Bezard E, Brotchie J, Calon F, Collingridge GL, Ferger B, Hengerer B, Hirsch E, Jenner P, Le Novère N, Obeso JA, Schwarzschild MA, Spampinato U, Davidai G. Novel pharmacological targets for the treatment of Parkinson's disease. Nature Reviews. Drug Discovery. 5: 845-54. PMID 17016425 DOI: 10.1038/Nrd2087  0.409
2006 Ascherio A, Chen H, Weisskopf MG, O'Reilly E, McCullough ML, Calle EE, Schwarzschild MA, Thun MJ. Pesticide exposure and risk for Parkinson's disease. Annals of Neurology. 60: 197-203. PMID 16802290 DOI: 10.1002/Ana.20904  0.444
2006 Chen H, Zhang SM, Schwarzschild MA, Hernán MA, Ascherio A. Survival of Parkinson's disease patients in a large prospective cohort of male health professionals. Movement Disorders : Official Journal of the Movement Disorder Society. 21: 1002-7. PMID 16602107 DOI: 10.1002/Mds.20881  0.455
2006 Chen H, Schernhammer E, Schwarzschild MA, Ascherio A. A prospective study of night shift work, sleep duration, and risk of Parkinson's disease. American Journal of Epidemiology. 163: 726-30. PMID 16495472 DOI: 10.1093/Aje/Kwj096  0.316
2006 Xu K, Xu Y, Brown-Jermyn D, Chen JF, Ascherio A, Dluzen DE, Schwarzschild MA. Estrogen prevents neuroprotection by caffeine in the mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 26: 535-41. PMID 16407551 DOI: 10.1523/Jneurosci.3008-05.2006  0.438
2006 Yu L, Schwarzschild MA, Chen JF. Cross-sensitization between caffeine- and L-dopa-induced behaviors in hemiparkinsonian mice. Neuroscience Letters. 393: 31-5. PMID 16236444 DOI: 10.1016/J.Neulet.2005.09.036  0.331
2006 Weisskopf MG, O'Reilly E, McCullough ML, Calle EE, Thun MJ, Schwarzschild MA, Ascherio A. Prospective Study Of Education, Occupation, and Risk of Parkinson's Disease American Journal of Epidemiology. 163. DOI: 10.1093/Aje/163.Suppl_11.S178-C  0.373
2005 Kachroo A, Orlando LR, Grandy DK, Chen JF, Young AB, Schwarzschild MA. Interactions between metabotropic glutamate 5 and adenosine A2A receptors in normal and parkinsonian mice. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 25: 10414-9. PMID 16280580 DOI: 10.1523/Jneurosci.3660-05.2005  0.301
2005 Chen H, Jacobs E, Schwarzschild MA, McCullough ML, Calle EE, Thun MJ, Ascherio A. Nonsteroidal antiinflammatory drug use and the risk for Parkinson's disease. Annals of Neurology. 58: 963-7. PMID 16240369 DOI: 10.1002/Ana.20682  0.45
2005 Hauser RA, Schwarzschild MA. Adenosine A2A receptor antagonists for Parkinson's disease: rationale, therapeutic potential and clinical experience. Drugs & Aging. 22: 471-482. PMID 15974638 DOI: 10.2165/00002512-200522060-00002  0.48
2005 Xu K, Bastia E, Schwarzschild M. Therapeutic potential of adenosine A(2A) receptor antagonists in Parkinson's disease. Pharmacology & Therapeutics. 105: 267-310. PMID 15737407 DOI: 10.1016/J.Pharmthera.2004.10.007  0.422
2005 Chen H, Zhang SM, Schwarzschild MA, Hernán MA, Ascherio A. Physical activity and the risk of Parkinson disease Neurology. 64: 664-669. PMID 15728289 DOI: 10.1212/01.Wnl.0000151960.28687.93  0.44
2004 Chen H, Zhang SM, Schwarzschild MA, Hernán MA, Logroscino G, Willett WC, Ascherio A. Folate Intake and Risk of Parkinson’s Disease American Journal of Epidemiology. 160: 368-375. PMID 15286022 DOI: 10.1093/Aje/Kwh213  0.399
2004 Chen H, Zhang SM, Schwarzschild MA, Hernán MA, Willett WC, Ascherio A. Obesity and the Risk of Parkinson’s Disease American Journal of Epidemiology. 159: 547-555. PMID 15003958 DOI: 10.1093/Aje/Kwh059  0.422
2004 Dunah AW, Sirianni AC, Fienberg AA, Bastia E, Schwarzschild MA, Standaert DG. Dopamine D1-dependent trafficking of striatal N-methyl-D-aspartate glutamate receptors requires Fyn protein tyrosine kinase but not DARPP-32. Molecular Pharmacology. 65: 121-9. PMID 14722243 DOI: 10.1124/Mol.65.1.121  0.322
2003 Chen JF, Fredduzzi S, Bastia E, Yu L, Moratalla R, Ongini E, Schwarzschild MA. Adenosine A2A receptors in neuroadaptation to repeated dopaminergic stimulation: implications for the treatment of dyskinesias in Parkinson's disease. Neurology. 61: S74-81. PMID 14663016 DOI: 10.1212/01.Wnl.0000095218.26363.7B  0.424
2003 Castagnoli N, Petzer JP, Steyn S, Castagnoli K, Chen JF, Schwarzschild MA, Van der Schyf CJ. Monoamine oxidase B inhibition and neuroprotection: studies on selective adenosine A2A receptor antagonists. Neurology. 61: S62-8. PMID 14663013 DOI: 10.1212/01.Wnl.0000095215.97585.59  0.437
2003 Schwarzschild MA, Xu K, Oztas E, Petzer JP, Castagnoli K, Castagnoli N, Chen JF. Neuroprotection by caffeine and more specific A2A receptor antagonists in animal models of Parkinson's disease. Neurology. 61: S55-61. PMID 14663012 DOI: 10.1212/01.Wnl.0000095214.53646.72  0.471
2003 Chen J, Chase T, Schwarzschild M. J. Stephen Fink, MD, PhD (1950–2002) Neurology. 61. PMID 14663000 DOI: 10.1212/01.Wnl.0000095201.55121.8A  0.379
2003 Bibbiani F, Oh JD, Petzer JP, Castagnoli N, Chen JF, Schwarzschild MA, Chase TN. A2A antagonist prevents dopamine agonist-induced motor complications in animal models of Parkinson's disease. Experimental Neurology. 184: 285-94. PMID 14637099 DOI: 10.1016/S0014-4886(03)00250-4  0.389
2003 Chen H, Zhang SM, Hernán MA, Schwarzschild MA, Willett WC, Colditz GA, Speizer FE, Ascherio A. Nonsteroidal Anti-inflammatory Drugs and the Risk of Parkinson Disease Jama Neurology. 60: 1059-1064. PMID 12925360 DOI: 10.1001/Archneur.60.8.1059  0.458
2003 Hernán MA, Chen H, Schwarzschild MA, Ascherio A. Alcohol consumption and the incidence of Parkinson's disease Annals of Neurology. 54: 170-175. PMID 12891669 DOI: 10.1002/Ana.10611  0.43
2003 Weisskopf MG, Chen H, Schwarzschild MA, Kawachi I, Ascherio A. Prospective study of phobic anxiety and risk of Parkinson's disease Movement Disorders. 18: 646-651. PMID 12784267 DOI: 10.1002/Mds.10425  0.449
2003 Ascherio A, Chen H, Schwarzschild MA, Zhang SM, Colditz GA, Speizer FE. Caffeine, postmenopausal estrogen, and risk of Parkinson's disease Neurology. 60: 790-795. PMID 12629235 DOI: 10.1212/01.Wnl.0000046523.05125.87  0.399
2003 Petzer JP, Steyn S, Castagnoli KP, Chen JF, Schwarzschild MA, Van der Schyf CJ, Castagnoli N. Inhibition of monoamine oxidase B by selective adenosine A2A receptor antagonists. Bioorganic & Medicinal Chemistry. 11: 1299-310. PMID 12628657 DOI: 10.1016/S0968-0896(02)00648-X  0.376
2003 Bastia E, Schwarzschild MA. DARPP chocolate: a caffeinated morsel of striatal signaling. Science Signaling. 2003. PMID 12527819 DOI: 10.1126/Stke.2003.165.Pe2  0.301
2003 Gomez-Isla T, Irizarry MC, Mariash A, Cheung B, Soto O, Schrump S, Sondel J, Kotilinek L, Day J, Schwarzschild MA, Cha JH, Newell K, Miller DW, Uéda K, Young AB, et al. Motor dysfunction and gliosis with preserved dopaminergic markers in human alpha-synuclein A30P transgenic mice. Neurobiology of Aging. 24: 245-58. PMID 12498958 DOI: 10.1016/S0197-4580(02)00091-X  0.501
2003 Schwarzschild MA, Chen JF, Chase TN. A2A antagonists for PD: A prime example of translational neuroscience Neurology. 61: S3-S4. DOI: 10.1212/01.Wnl.0000095202.94814.0F  0.438
2003 Chen J, Schwarzschild MA. Gene knockout approach to adenosine A2A receptors in Parkinson's disease Drug Development Research. 58: 354-367. DOI: 10.1002/Ddr.10215  0.391
2002 Chen JF, Steyn S, Staal R, Petzer JP, Xu K, Van Der Schyf CJ, Castagnoli K, Sonsalla PK, Castagnoli N, Schwarzschild MA. 8-(3-Chlorostyryl)caffeine may attenuate MPTP neurotoxicity through dual actions of monoamine oxidase inhibition and A2A receptor antagonism. The Journal of Biological Chemistry. 277: 36040-4. PMID 12130655 DOI: 10.1074/Jbc.M206830200  0.32
2002 Schwarzschild MA, Chen J, Ascherio A. Caffeinated clues and the promise of adenosine A2A antagonists in PD Neurology. 58: 1154-1160. PMID 11971080 DOI: 10.1212/Wnl.58.8.1154  0.461
2002 Xu K, Xu YH, Chen JF, Schwarzschild MA. Caffeine's neuroprotection against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity shows no tolerance to chronic caffeine administration in mice. Neuroscience Letters. 322: 13-6. PMID 11958832 DOI: 10.1016/S0304-3940(02)00069-1  0.309
2001 Gearan T, Castillo OA, Schwarzschild MA. The parkinsonian neurotoxin, MPP+ induces phosphorylated c-Jun in dopaminergric neurons of mesencephalic cultures. Parkinsonism & Related Disorders. 8: 19-22. PMID 11472876 DOI: 10.1016/S1353-8020(00)00078-X  0.334
2001 Chen J, Xu K, Petzer JP, Staal R, Xu Y, Beilstein M, Sonsalla PK, Castagnoli K, Castagnoli N, Schwarzschild MA. Neuroprotection by Caffeine and A2AAdenosine Receptor Inactivation in a Model of Parkinson's Disease The Journal of Neuroscience. 21: RC143-RC143. DOI: 10.1523/Jneurosci.21-10-J0001.2001  0.486
2001 Ongini E, Monopoli A, Impagnatiello F, Fredduzzi S, Schwarzschild M, Chen J. Dual actions of A2A adenosine receptor antagonists on motor dysfunction and neurodegenerative processes Drug Development Research. 52: 379-386. DOI: 10.1002/Ddr.1137  0.341
Show low-probability matches.